Mok TS, Kim D, Wu Y, et al. Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in ALK+ Lung Cancer: Updated Results from PROFILE 1014. ESMO 2017, abstract LBA50.
Vaccins tegen kanker opnieuw onder de aandacht
nov 2022 | Longoncologie, Mesothelioom, Vaccinatie